{"id":"NCT03105128","sponsor":"AbbVie","briefTitle":"A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-10","primaryCompletion":"2020-11-09","completion":"2021-04-14","firstPosted":"2017-04-07","resultsPosted":"2022-07-06","lastUpdate":"2022-07-06"},"enrollment":931,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"placebo for risankizumab","otherNames":[]},{"type":"DRUG","name":"risankizumab IV","otherNames":["ABBV-066 BI 655066","SKYRIZI"]},{"type":"DRUG","name":"risankizumab SC","otherNames":["ABBV-066 BI 655066","SKYRIZI"]}],"arms":[{"label":"Risankizumab Dose 1 (Period 1)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 2 (Period 1)","type":"EXPERIMENTAL"},{"label":"Placebo (Period 1)","type":"PLACEBO_COMPARATOR"},{"label":"Risankizumab Dose 1 (Period 2)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 2 (Period 2)","type":"EXPERIMENTAL"},{"label":"Risankizumab Dose 3 (Period 2)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).","primaryOutcome":{"measure":"US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo (Period 1)","deltaMin":24.6,"sd":null},{"arm":"Risankizumab 600mg (Period 1)","deltaMin":45.2,"sd":null},{"arm":"Risankizumab 1200mg (Period 1)","deltaMin":41.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":475,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Estonia","Germany","Greece","Hong Kong","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Ukraine","United Kingdom"]},"refs":{"pmids":["39909280","39485390","39131711","39105965","37368103","37296268","35644154"],"seeAlso":["https://www.rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":186},"commonTop":["HEADACHE","NASOPHARYNGITIS","NAUSEA","ANAEMIA","CROHN'S DISEASE"]}}